Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost ...
Publications
3 shownAnti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
We report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma. Antitumor activity was documented. (F...
A microRNA expression signature of human solid tumors defines cancer gene targets
Small noncoding microRNAs (miRNAs) can contribute to cancer development and progression and are differentially expressed in normal tissues and cancers. From a large-scale miRnom...
Frequent Co-Authors
Researcher Info
- h-index
- 3
- Publications
- 3
- Citations
- 9,438
- Institution
- The Ohio State University
External Links
Identifiers
- ORCID
- 0000-0002-9115-0295
Impact Metrics
h-index
3
h-index: Number of publications with at least h citations each.